Report Content
Chapter 1 Methodology
1.1 Market definition
1.2 Base estimates & calculations
1.3 Forecast parameters
1.4 COVID-19 impact analysis at global level
1.5 Data validation
1.6 Data Sources
1.6.1 Primary
1.6.2 Secondary
1.6.2.1 Paid sources
1.6.2.2 Public sources
Chapter 2 Executive Summary
2.1 Actinic keratosis treatment industry 3600 synopsis, 2018 – 2032
2.1.1 Business trends
2.1.2 Regional trends
2.1.3 Therapy trends
2.1.4 Drug class trends
2.1.5 End-use trends
Chapter 3 Actinic Keratosis Treatment Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Rising prevalence of actinic keratosis
3.2.1.2 Favourable reimbursement policies
3.2.1.3 Growing demand for minimally invasive procedures
3.2.1.4 Increasing number of drug approvals and novel therapies
3.2.2 Industry pitfalls & challenges
3.2.2.1 Risk and side effects associated with available treatment options
3.3 Growth potential analysis
3.3.1 By therapy
3.3.2 By drug class
3.3.3 By end-use
3.4 COVID- 19 impact analysis
3.5 Technological advancements
3.6 Regulatory landscape
3.6.1 U.S.
3.6.2 Europe
3.7 Pipeline analysis
3.8 Porter's analysis
3.9 PESTEL analysis
Chapter 4 Competitive Landscape, 2022
4.1 Introduction
4.2 Company matrix analysis, 2022
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
4.6 Strategic outlook matrix
Chapter 5 Actinic Keratosis Treatment Market Size and Forecast, By Therapy (USD Million)
5.1 Key trends, by therapy
5.2 Photodynamic Therapy
5.3 Surgery
5.4 Topical Medications
Chapter 6 Actinic Keratosis Treatment Market Size and Forecast, By Drug Class (USD Million)
6.1 Key trends, by drug class
6.2 NSAIDs
6.3 Nucleoside Metabolic Inhibitor
6.4 Immune Response Modifiers
6.5 Photoenhancers
Chapter 7 Actinic Keratosis Treatment Market Size and Forecast, By End-use (USD Million)
7.1 Key trends, by end-use
7.2 Hospitals and Oncology Centers
7.3 Dermatology Clinics
7.4 Homecare
7.5 Others
Chapter 8 Actinic Keratosis Treatment Market Size and Forecast, By Region (USD Million)
8.1 Key trends, by region
8.2 North America
8.2.1 U.S.
8.2.2 Canada
8.3 Europe
8.3.1 Germany
8.3.2 UK
8.3.3 France
8.3.4 Spain
8.3.5 Italy
8.3.6 Poland
8.3.7 Sweden
8.3.8 The Netherlands
8.3.9 Rest of Europe
8.4 Asia Pacific
8.4.1 Japan
8.4.2 China
8.4.3 India
8.4.4 Australia
8.4.5 South Korea
8.4.6 Indonesia
8.4.7 Philippines
8.4.8 Malaysia
8.4.9 Rest of Asia Pacific
8.5 Latin America
8.5.1 Brazil
8.5.2 Mexico
8.5.3 Argentina
8.5.4 Columbia
8.5.5 Chile
8.5.6 Peru
8.5.7 Rest of Latin America
8.6 MEA
8.6.1 South Africa
8.6.2 Saudi Arabia
8.6.3 UAE
8.6.4 Israel
8.6.5 Turkey
8.6.6 Iran
8.6.7 Rest of MEA
Chapter 9 Company Profiles
9.1 Sun Pharmaceutical Industries Ltd
9.2 Galderma S.A.
9.3 Almirall, S.A.
9.4 LEO Pharma A/S
9.5 Biofrontera AG
9.6 Ortho Dermatologics (Bausch Health Companies Inc.)
9.7 Hill Dermaceuticals, Inc.
9.8 Cipher Pharmaceuticals Inc.
9.9 Spear Pharmaceuticals
9.10 Tolmar Inc
9.11 Vidac Pharma Holding PLC
9.12 Athenex, Inc.
